These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 12823782)
21. FDA panel recommends two new cancer drugs for approval. Finkelstein JB J Natl Cancer Inst; 2001 Feb; 93(3):175-6. PubMed ID: 11158184 [No Abstract] [Full Text] [Related]
25. Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study. Kim SJ; Kim K; Kim BS; Suh C; Huh J; Ko YH; Kim WS Ann Oncol; 2009 Feb; 20(2):390-2. PubMed ID: 19211502 [No Abstract] [Full Text] [Related]
27. Alemtuzumab: what is the secret to safe therapy? Elter T; Hallek M; Montillo M Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865 [TBL] [Abstract][Full Text] [Related]
31. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Gibbs SD; Westerman DA; McCormack C; Seymour JF; Miles Prince H Br J Haematol; 2005 Jul; 130(1):87-91. PubMed ID: 15982349 [TBL] [Abstract][Full Text] [Related]